NZ805649A - Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea - Google Patents
Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]ureaInfo
- Publication number
- NZ805649A NZ805649A NZ805649A NZ80564919A NZ805649A NZ 805649 A NZ805649 A NZ 805649A NZ 805649 A NZ805649 A NZ 805649A NZ 80564919 A NZ80564919 A NZ 80564919A NZ 805649 A NZ805649 A NZ 805649A
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- cyclodextrin
- dimorpholin
- triazin
- piperidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681722P | 2018-06-07 | 2018-06-07 | |
| US201862754651P | 2018-11-02 | 2018-11-02 | |
| US201962796133P | 2019-01-24 | 2019-01-24 | |
| US201962841882P | 2019-05-02 | 2019-05-02 | |
| NZ770000A NZ770000B2 (en) | 2019-06-04 | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ805649A true NZ805649A (en) | 2024-11-29 |
Family
ID=67402968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ805649A NZ805649A (en) | 2018-06-07 | 2019-06-04 | Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US12109308B2 (https=) |
| EP (3) | EP4249069B1 (https=) |
| JP (2) | JP7423200B2 (https=) |
| KR (2) | KR20230142810A (https=) |
| CN (2) | CN116270452A (https=) |
| AU (2) | AU2019283550B2 (https=) |
| BR (1) | BR112020023891A2 (https=) |
| CA (1) | CA3102527A1 (https=) |
| DK (2) | DK4249069T3 (https=) |
| ES (2) | ES3057278T3 (https=) |
| FI (2) | FI3810089T3 (https=) |
| HR (2) | HRP20251602T1 (https=) |
| HU (1) | HUE063493T2 (https=) |
| IL (1) | IL279270A (https=) |
| LT (2) | LT3810089T (https=) |
| MX (2) | MX2020013238A (https=) |
| NZ (1) | NZ805649A (https=) |
| PL (2) | PL3810089T3 (https=) |
| PT (2) | PT3810089T (https=) |
| RS (2) | RS64692B1 (https=) |
| SG (1) | SG11202011256RA (https=) |
| SI (2) | SI4249069T1 (https=) |
| SM (2) | SMT202300307T1 (https=) |
| TW (1) | TWI696469B (https=) |
| WO (1) | WO2019234632A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3672571T1 (sl) | 2017-08-25 | 2022-01-31 | Pfizer Inc. | Farmacevtska vodna raztopina, ki vsebuje 1-(4-((4-(dimetilamino) piperdin-1-il)karbonil)fenil)-3-(4-(4,6-dimorfolin-4-il-1,3, 5-triazin-2-il)fenil)sečnino |
| CA3227191A1 (en) | 2021-07-26 | 2023-02-02 | Celcuity Inc. | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
| WO2025128712A1 (en) | 2023-12-12 | 2025-06-19 | Celcuity Inc. | Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea |
| US20260053814A1 (en) | 2024-08-21 | 2026-02-26 | Celcuity Inc. | Treatment regimens for gedatolisib in hormonally-driven disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| WO2003015828A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin |
| US20070111965A1 (en) * | 2005-11-15 | 2007-05-17 | Kipp James E | Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| LT2294072T (lt) | 2008-05-23 | 2017-06-12 | Wyeth Llc | Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai |
| US10022381B2 (en) | 2008-05-23 | 2018-07-17 | Pfizer Inc. | Triazine compounds as PI3 kinase and mTOR inhibitors |
| WO2010096619A1 (en) | 2009-02-23 | 2010-08-26 | Wyeth Llc | Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
| WO2014121235A2 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| PE20170312A1 (es) * | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
| ES2881214T3 (es) * | 2014-12-17 | 2021-11-29 | Pfizer | Formulaciones de un inhibidor de PI3K/mTOR para la administración intravenosa |
| KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
| SI3672571T1 (sl) * | 2017-08-25 | 2022-01-31 | Pfizer Inc. | Farmacevtska vodna raztopina, ki vsebuje 1-(4-((4-(dimetilamino) piperdin-1-il)karbonil)fenil)-3-(4-(4,6-dimorfolin-4-il-1,3, 5-triazin-2-il)fenil)sečnino |
-
2019
- 2019-06-04 EP EP23176968.8A patent/EP4249069B1/en active Active
- 2019-06-04 SM SM20230307T patent/SMT202300307T1/it unknown
- 2019-06-04 BR BR112020023891-0A patent/BR112020023891A2/pt unknown
- 2019-06-04 LT LTEPPCT/IB2019/054643T patent/LT3810089T/lt unknown
- 2019-06-04 MX MX2020013238A patent/MX2020013238A/es unknown
- 2019-06-04 NZ NZ805649A patent/NZ805649A/en unknown
- 2019-06-04 KR KR1020237032620A patent/KR20230142810A/ko not_active Ceased
- 2019-06-04 CN CN202310372451.7A patent/CN116270452A/zh active Pending
- 2019-06-04 RS RS20230948A patent/RS64692B1/sr unknown
- 2019-06-04 ES ES23176968T patent/ES3057278T3/es active Active
- 2019-06-04 PT PT197428980T patent/PT3810089T/pt unknown
- 2019-06-04 PL PL19742898.0T patent/PL3810089T3/pl unknown
- 2019-06-04 WO PCT/IB2019/054643 patent/WO2019234632A1/en not_active Ceased
- 2019-06-04 DK DK23176968.8T patent/DK4249069T3/da active
- 2019-06-04 SI SI201931002T patent/SI4249069T1/sl unknown
- 2019-06-04 RS RS20251283A patent/RS67535B1/sr unknown
- 2019-06-04 SM SM20250473T patent/SMT202500473T1/it unknown
- 2019-06-04 AU AU2019283550A patent/AU2019283550B2/en active Active
- 2019-06-04 HU HUE19742898A patent/HUE063493T2/hu unknown
- 2019-06-04 LT LTEP23176968.8T patent/LT4249069T/lt unknown
- 2019-06-04 SI SI201930595T patent/SI3810089T1/sl unknown
- 2019-06-04 HR HRP20251602TT patent/HRP20251602T1/hr unknown
- 2019-06-04 CA CA3102527A patent/CA3102527A1/en active Pending
- 2019-06-04 US US15/734,147 patent/US12109308B2/en active Active
- 2019-06-04 PL PL23176968.8T patent/PL4249069T3/pl unknown
- 2019-06-04 EP EP19742898.0A patent/EP3810089B1/en active Active
- 2019-06-04 KR KR1020207037914A patent/KR102583563B1/ko active Active
- 2019-06-04 FI FIEP19742898.0T patent/FI3810089T3/fi active
- 2019-06-04 CN CN201980037499.4A patent/CN112218618B/zh active Active
- 2019-06-04 PT PT231769688T patent/PT4249069T/pt unknown
- 2019-06-04 EP EP25207215.2A patent/EP4649940A3/en active Pending
- 2019-06-04 SG SG11202011256RA patent/SG11202011256RA/en unknown
- 2019-06-04 FI FIEP23176968.8T patent/FI4249069T3/fi active
- 2019-06-04 HR HRP20231337TT patent/HRP20231337T1/hr unknown
- 2019-06-04 DK DK19742898.0T patent/DK3810089T3/da active
- 2019-06-04 ES ES19742898T patent/ES2956225T3/es active Active
- 2019-06-05 JP JP2019105034A patent/JP7423200B2/ja active Active
- 2019-06-06 TW TW108119644A patent/TWI696469B/zh active
-
2020
- 2020-12-04 MX MX2023012527A patent/MX2023012527A/es unknown
- 2020-12-07 IL IL279270A patent/IL279270A/en unknown
-
2022
- 2022-08-03 AU AU2022211854A patent/AU2022211854B2/en active Active
-
2023
- 2023-08-14 JP JP2023132078A patent/JP7559162B2/ja active Active
-
2024
- 2024-09-05 US US18/825,795 patent/US20250064732A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ805649A (en) | Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| KR101798951B1 (ko) | 벤다무스틴 환형다당류 조성물 | |
| EP2131849B1 (en) | Compositions and methods for delivery of anti-cancer agents | |
| JP2016525105A (ja) | 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物 | |
| CN1505513A (zh) | 注射用西洛他唑水性制剂 | |
| JP2019151672A (ja) | がん治療薬 | |
| US20230277674A1 (en) | Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists | |
| JP2019218338A5 (https=) | ||
| EP4079293B1 (en) | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrole-3-yl)-n-methylmethaneamine | |
| CZ297788B6 (cs) | Farmaceutický prostredek pro parenterální podání | |
| HRP20211985T1 (hr) | Farmaceutska vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu | |
| KR20220104114A (ko) | 안과용 조성물 | |
| US20070129328A1 (en) | Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration | |
| CN114173761A (zh) | 包含乌地那非的药物组合物 | |
| KR20090050070A (ko) | 항종양제를 포함하는 수성 제제 | |
| US6828311B2 (en) | Formulation for the parenteral application of a sodium channel blocker | |
| KR102363026B1 (ko) | 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 전립선암 예방 또는 치료용 약학적 조성물 | |
| JP2023533498A5 (https=) | ||
| HK40100360A (zh) | 包含1-(5-(2，4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的注射用新配制物 | |
| TW200400029A (en) | New formulation for the parenteral application of a sodium channel blocker | |
| HK1064056B (en) | An aqueous pharmaceutical preparation of cilostazol for parenteral use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 JUN 2026 BY COMPUTER PACKAGES INC Effective date: 20250517 |